Krishna Institute of Medical Sciences (KIMS) announced its financial results for Q2 FY25, showcasing a strong performance. The company achieved a consolidated revenue of ₹782 crore, marking a 19.4% increase compared to the same quarter last year and a 12.9% rise QoQ. EBITDA for the quarter reached ₹223 crore, reflecting a YoY growth of 23.8% and a QoQ increase of 21.2%. The EBITDA margin improved to 28.5% from 27.5% in Q2 FY24 and 26.6% in Q1 FY25.
Additionally, KIMS reported a PAT of ₹121 crore, up 16.7% YoY from ₹101 crore and up 27.4% QoQ. The company’s EPS grew by 16.7% YoY, reaching ₹3 per share.
Other highlights include:
- EBITDA margin (excluding other income) at 28.1%, up from 27.2% in Q2 FY24.
- Cash and cash equivalents stood at ₹90 crore as of Q2 FY25.
These results demonstrate KIMS’s robust operational and financial growth, reinforcing its position in the healthcare sector.
